Travere Therapeutics, Inc. Stock Analysis & AI Score
Travere Therapeutics, Inc. (TVTX) has an ST Score of 58.4 (B-), driven by its Growth (A+) and held back by its Valuation (D). Analysts rate it Buy with a $70.60 price target (+16.5% upside).
Composite rating from 8 factors. Tap a factor to see the metrics behind its grade.
Company Information
| Employees | — |
| CEO | — |
| Sector | Healthcare |
| Industry | Biotechnology |
| IPO Date | — |
| Website | — |
| Country | — |
| Exchange | NASDAQ |
SEC Filings
Annual Report (10-K)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
Quarterly Report (10-Q)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
ST Score
Travere Therapeutics, Inc. (TVTX) has an ST Score of 58.4 (B-), driven by its Growth (A+) and held back by its Valuation (D). Analysts rate it Buy with a $70.60 price target (+16.5% upside).
- Strongest
- GrowthA+
- Weakest
- ValuationD
All factor grades
- GrowthA+
- ProfitabilityA-
- MomentumA-
- ForecastB-
- Financial StrengthD+
- ValuationD
- Piotroski5/9
Contact
TVTX stock: frequently asked questions
What is TVTX's ST Score?
Travere Therapeutics, Inc. (TVTX) has an ST Score of 58.4 (B-), on our 0–100 scale where higher is stronger. The ST Score combines eight factor grades — valuation, profitability, financial strength, momentum, growth, forecast, sentiment and Piotroski — into a single A+ to F rating.
Is TVTX a buy, hold, or sell?
Analysts rate TVTX a Buy, with a price target of $70.60 (+16.5% vs the current price). Our ST Score grades it B- (58.4/100). The ST Score is a data-driven signal, not a recommendation.
What are TVTX's factor grades?
Valuation D, Profitability A-, Financial Strength D+, Momentum A-, Growth A+, Forecast B-.
What is TVTX's valuation grade?
Travere Therapeutics, Inc. (TVTX) earns a valuation grade of D, measured against Biotechnology peers. The valuation factor looks at multiples such as P/E, P/S, P/B, EV/EBITDA and free cash flow yield.
What is TVTX's growth grade?
Travere Therapeutics, Inc. (TVTX) earns a growth grade of A+, measured against Biotechnology peers. The growth factor looks at revenue, earnings and cash flow growth over recent quarters and years.
What is TVTX's profitability grade?
Travere Therapeutics, Inc. (TVTX) earns a profitability grade of A-, measured against Biotechnology peers. The profitability factor looks at margins and returns such as gross margin, net margin, ROE and ROIC.
What is TVTX's financial strength grade?
Travere Therapeutics, Inc. (TVTX) earns a financial strength grade of D+, measured against Biotechnology peers. The financial strength factor looks at debt levels, liquidity and coverage ratios.
What is the analyst price target for TVTX?
The average analyst price target for Travere Therapeutics, Inc. (TVTX) is $70.60 from 18 analysts, which is +16.5% versus the recent price of $60.62.
What is TVTX's Piotroski score?
Travere Therapeutics, Inc. (TVTX) has a Piotroski F-Score of 5 out of 9. The Piotroski score checks nine accounting signals covering profitability, leverage and operating efficiency; scores of 8–9 are considered strong and 0–2 weak.